Shots:

• Skyline to receive an upfront along with equity investment & is eligible to receive pre-specified fees for R&D, regulatory and commercial milestones along with royalties on sales in its territories. The companies will advance the programs through clinical development in their pre-defined territories
• BioMarin gets the rights to commercialize therapeutic products in territories, including the US, EU, and Latin America. Skyline will be responsible for commercialization in the Asia-Pacific region
• The collaboration will use Skyline Therapeutics' integrated AAV gene therapy platform & BioMarin’s capabilities to develop gene therapies for the treatment of genetic DCM

Ref: PR Newswire | Image: UCLB